Mobile

A Study to Compare ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or...

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003335-35

A Study to Compare ABT-494 to Placebo in Subjects with Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who have an Inadequate Response or Intolerance to Biologic DMARDs (SELECT-BEYOND)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To compare the safety and efficacy of ABT-494 versus placebo for the treatment of signs and symptoms of subjects with moderately to severely active rheumatoid arthritis (RA) who are on a stable dose of conventional synthetic disease- modifying anti-rheumatic drugs (csDMARDs) and have an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drugs (bDMARDs). • To evaluate the long-term safety, tolerability, and efficacy of ABT-494 in subjects with RA.

Critère d'inclusion

  • Moderately to Severely Active Rheumatoid Arthritis (RA)

Liens